Health Condition 1: N990- Postprocedural (acute) (chronic) kidney failure
Conditions
Interventions
None listed
Sponsors
Manipal College of Pharmaceutical Sciences
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients who are on tacrolimus therapy in the department of Nephrology. 2. These patients are stable and willing to participate in the study.
Exclusion criteria
Exclusion criteria: 1. Patients who underwent multiorgan transplantation. 2. Patients under the age of 18
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Cyp3A5 genotyping 2. Tacrolimus concentration will be estimated from whole blood. 3. Factors influencing Tacrolimus Pharmacokinetics will be identified. 4. Population pharmacokinetic model will be developed using the factors that affect tacrolimus kinetics.Timepoint: 1. Genotyping for Cyp3A5 will be performed within 6 months from recruitment of the subject. 2. Tacrolimus concentration will be estimated during 3 regular follow up visits to the hospital from the date of recruitment. 3. Factors influencing Tacrolimus Pharmacokinetics will be identified within 36 months from the initiation of the study. 4. Population pharmacokinetic model will be developed within 36 months from the initiation of the study. | — |
Secondary
| Measure | Time frame |
|---|---|
| NilTimepoint: Nil | — |
Countries
India
Contacts
Public ContactSurulivelrajan M
Manipal academy of higher education
Outcome results
None listed